Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The field of glaucoma care is undergoing a major shift. Instead of relying on daily eye drops as first-line therapy — a strategy plagued by poor patient adherence and side effects — more specialists are turning to laser treatments, implantable drug-delivery devices, and minimally invasive surgery first. Landmark trial data and a 2025 consensus protocol are accelerating this "interventional glaucoma" movement, with better vision outcomes and quality of life for patients.
Glaucoma care is getting a makeover — and eye drops are no longer the default
Glaucoma affects an estimated 4.22 million Americans, yet only about half have been diagnosed. Even among those who are, adherence to daily eye drop therapy is notoriously poor — just 56% of newly diagnosed patients fill enough drops in year one, and only 31% stay consistent after that. Add in side effects like ocular surface toxicity, skin changes, and even depression, and it's clear the "drops first" model has real limitations.
Enter interventional glaucoma (IG): a growing movement that repositions laser therapy, implantable drug-delivery devices, and minimally invasive glaucoma surgery (MIGS) as front-line options, with drops used only as adjuncts. A 2025 Interventional Glaucoma Consensus Treatment Protocol now gives clinicians a practical roadmap, starting with selective laser trabeculoplasty (SLT) and escalating through procedural options before reaching traditional filtering surgery. Patients are increasingly on board too — many now actively prefer procedures over lifelong daily drops.
By the Numbers
Why it matters: With glaucoma prevalence set to rise and the ophthalmologist workforce expected to stay flat or shrink, shifting to more durable, procedure-based care isn't just clinically smarter — it's a practical necessity. Better IOP control earlier means fewer costly complications, less filtering surgery, and patients who can manage their condition without the daily burden of eye drops.
